Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910358 · ClinicalTrials.gov registry record · Phase 3
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
A Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Disc Medicine.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06910358: Recruiting Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Disc Medicine.
NCT06910358 is a Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) that is actively recruiting participants, run by Disc Medicine. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06910358, a Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), is actively recruiting participants, sponsored by Disc Medicine.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Participants will complete daily questionnaires and attend study visits for assessments.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DISC-1459
Study Locations (20)
California
- Marvel Clinical Research - Huntington Beach
- University of California San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- MetroBoston Clinical Partners - Boston
Other
- UZ Leuven - Leuven
- Children's Health Ireland (CHI) - Dublin
France
- CHU de Nantes - Hôtel Dieu, Service de dermatologie - Nantes
- Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard - Paris
Florida
- University of Miami Miller School of Medicine - Miami
Michigan
- Henry Ford Health System - Detroit
New York
- Mount Sinai Hospital - New York
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-04-04 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
What NCT06910358 shows while recruiting
NCT06910358 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Erythropoietic Protoporphyria (EPP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06910358 names 20 study sites across 16 states, led by California, Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT06910358 about?
NCT06910358 is a clinical study titled "Study of Bitopertin in Participants With EPP or XLP (APOLLO)". The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How ...
What is the current status of trial NCT06910358?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-04-04. Estimated completion is 2026-11.
What conditions does trial NCT06910358 study?
This clinical trial studies the following conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP).
What interventions are being tested in trial NCT06910358?
The interventions under investigation include: Placebo (DRUG), DISC-1459 (DRUG).
Who is sponsoring clinical trial NCT06910358?
This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910358 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythropoietic Protoporphyria (EPP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06910358's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI